Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

A judge who is married to a former Pfizer executive is overseeing Mangione’s federal pretrial hearings. But she won’t oversee ...

Why Kirk Spano sees Pfizer as one of the next big winners from AI and why he thinks investors should be selling cash secured ...

"Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

Sangamo Therapeutics Inc.’s stock sank sharply on the last day of 2025 as Pfizer Inc. handed back the rights to their collaborative gene therapy hemophilia A program. While it was another big loss to ...

TD Cowen keeps a Buy rating on Sangamo (SGMO) after Pfizer (PFE) decided to terminate the global collaboration and license agreement between ...